×
Lipocine Income Taxes 2012-2025 | LPCN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Lipocine income taxes from 2012 to 2025. Income taxes can be defined as the total amount of income tax expense for the given period.
View More
Lipocine Income Taxes 2012-2025 | LPCN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Lipocine income taxes from 2012 to 2025. Income taxes can be defined as the total amount of income tax expense for the given period.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$81.7B
Zoetis (ZTS)
$66.3B
Daiichi Sankyo, - (DSNKY)
$46.4B
Takeda Pharmaceutical (TAK)
$43.3B
BeOne Medicines - (ONC)
$32.9B
Sandoz Group AG (SDZNY)
$25.9B
Summit Therapeutics (SMMT)
$19.8B
Merck (MKKGY)
$16.5B
Shionogi (SGIOY)
$14.3B
Neurocrine Biosciences (NBIX)
$13.5B
United Therapeutics (UTHR)
$12.7B
Orion OYJ (ORINY)
$11.5B
IPSEN (IPSEY)
$10.8B
Stevanato Group S.p.A (STVN)
$7.6B
Grifols, S.A (GRFS)
$7.5B
Corcept Therapeutics (CORT)
$7.4B
Ionis Pharmaceuticals (IONS)
$6.9B
Madrigal Pharmaceuticals (MDGL)
$6.4B
Hikma Pharmaceuticals Plc (HKMPF)
$5.9B
Ono Pharmaceutical (OPHLF)
$5.2B
Soleno Therapeutics (SLNO)
$4.3B
Hypermarcas (HYPMY)
$3.1B
Crinetics Pharmaceuticals (CRNX)
$2.7B
Catalyst Pharmaceuticals (CPRX)
$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.5B
NewAmsterdam Pharma (NAMS)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.2B
Ocular Therapeutix (OCUL)
$1.9B
Endo (NDOI)
$1.8B
ARS Pharmaceuticals (SPRY)
$1.8B